secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0000950170-23-066553
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics dosed first participants in Phase 1 trial of SAB-142 for Type 1 Diabetes
--------------------------------------------------------------------------------

- First-in-human Phase 1 trial dosed in Australia; double-blind, placebo-controlled, single-ascending dose design.
- SAB-142 is a first-in-class fully-human anti-thymocyte immunoglobulin targeting immune cells that destroy pancreatic beta cells.
- Phase 1 assesses safety, tolerability, PK/PD, and aims to establish proof of biological activity in T1D.
- Company plans to file IND with FDA and CTA in UK/EU in 2024 to advance to Phase 2b study.
- Trial led by Dr. Kristi McLendon at Nucleus Network; SAB-142 has potential as disease-modifying treatment for T1D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023066553/0000950170-23-066553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017023066553/sabs-20231129.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer